On August 3, 2023, the Company and James Thorburn, the Company's Chief Financial Officer, mutually agreed that Mr. Thorburn will transition to a new role responsible for guiding the Company’s commercial scaling, operational leverage and DNA data storage business, once a new Chief Financial Officer is appointed.
Key facts
Extracted from this filing and checked against the source text.
Earnings ReleasesSEC 8-K Item 2.02confidence 0.9
Twist Bioscience Corp reported the third quarter of fiscal 2023 ended June 30, 2023 results: revenue $63.7 million.
Period
the third quarter of fiscal 2023 ended June 30, 2023
Revenue
$63.7 million
Result
reported results
Exact text from the filing
Century Archive workflow by the end of calendar 2023. " FISCAL 2023 THIRD QUARTER FINANCIAL RESULTS • Orders: Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 million for the same period of fiscal 2022 . • Revenue: Total revenues for the third quarter of fiscal 2023 were $63.7 million compared to $56.1 million for the
James Thorburn changed role as Chief Financial Officer at Twist Bioscience Corp.
Action
transition to a new role
Role
Chief Financial Officer
Exact text from the filing
On August 3, 2023, the Company and James Thorburn, the Company's Chief Financial Officer, mutually agreed that Mr. Thorburn will transition to a new role responsible for guiding the Company’s commercial scaling, operational leverage and DNA data storage business, once a new Chief Financial Officer is appointed.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.